Dermata Therapeutics, Inc.
DRMA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $8,204 | $4,070 | $5,651 | $3,459 |
| G&A Expenses | $0 | $3,972 | $0 | $0 |
| SG&A Expenses | $4,310 | $3,972 | $4,023 | $4,398 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $12,513 | $8,042 | $9,674 | $7,857 |
| Operating Income | -$12,513 | -$8,042 | -$9,674 | -$7,857 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $226 | $247 | $64 | -$46 |
| Pre-Tax Income | -$12,287 | -$7,795 | -$9,611 | -$7,902 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$12,287 | -$7,795 | -$9,611 | -$7,902 |
| % Margin | – | – | – | – |
| EPS | -80.32 | -401.8 | -139.2 | -152.7 |
| % Growth | 80% | -188.6% | 8.8% | – |
| EPS Diluted | -80.32 | -399.81 | -139.2 | -152.7 |
| Weighted Avg Shares Out | 153 | 19 | 69 | 52 |
| Weighted Avg Shares Out Dil | 153 | 19 | 69 | 52 |
| Supplemental Information | – | – | – | – |
| Interest Income | $226 | $247 | $0 | $0 |
| Interest Expense | $0 | $0 | -$64 | $46 |
| Depreciation & Amortization | $0 | $8,042 | $0 | $0 |
| EBITDA | -$12,287 | $247 | -$9,611 | -$7,857 |
| % Margin | – | – | – | – |